Bradykinin enhances sympathetic neurotransmission in rat blood vessels

Yasuo Kansui, Koji Fujii, Kenichi Goto, Isao Abe

研究成果: ジャーナルへの寄稿記事

7 引用 (Scopus)

抄録

Bradykinin evokes endothelium-dependent relaxation in some vascular beds; on the other hand, the possibility has been demonstrated that in certain organs, such as the adrenal medulla or atria, bradykinin may enhance transmitter release from the sympathetic nerves. We hypothesized that bradykinin may also enhance postganglionic sympathetic neurotransmission in blood vessels. To test this hypothesis, we recorded excitatory junction potentials (EJPs), a measure of sympathetic purinergic neurotransmission, in rat mesenteric resistance arteries with a conventional microelectrode technique. EJPs were elicited by repetitive perivascular nerve stimulation (1 Hz, 20 to 50 V, 30 to 60 μs, 11 pulses). In this preparation, bradykinin (10-7 or 10-6 mol/L) significantly enhanced the amplitude of EJPs without altering the resting membrane potential. This effect of bradykinin was blocked by Hoe 140, a bradykinin B2 receptor antagonist, but not by des-Arg9,[Leu8]-bradykinin, a bradykinin B1 receptor antagonist. The cyclooxygenase inhibitor indomethacin or NO synthase inhibitor NG-nitro-L-arginine did not alter the effect of bradykinin. Captopril, an ACE inhibitor, but not candesartan, an angiotensin II type 1 receptor antagonist, enhanced the action of a low concentration (10-8 mol/L) of bradykinin on EJPs. These findings suggest that in rat mesenteric resistance arteries, bradykinin enhances sympathetic purinergic neurotransmission, presumably through presynaptic bradykinin B2 receptors. The clinical relevance of the present findings remains unclear; however, the fact that the ACE inhibitor, but not the angiotensin II type 1 receptor antagonist, enhanced the action of bradykinin on sympathetic neurotransmission may warrant further investigation.

元の言語英語
ページ(範囲)29-34
ページ数6
ジャーナルHypertension
39
発行部数1
DOI
出版物ステータス出版済み - 2 5 2002

Fingerprint

Bradykinin
Synaptic Transmission
Blood Vessels
Angiotensin II Type 1 Receptor Blockers
Mesenteric Arteries
Angiotensin-Converting Enzyme Inhibitors
Bradykinin B2 Receptors
Adrenal Medulla
Cyclooxygenase Inhibitors
Nitroarginine
Captopril
Microelectrodes
Nitric Oxide Synthase
Indomethacin
Membrane Potentials
Endothelium

All Science Journal Classification (ASJC) codes

  • Internal Medicine

これを引用

Bradykinin enhances sympathetic neurotransmission in rat blood vessels. / Kansui, Yasuo; Fujii, Koji; Goto, Kenichi; Abe, Isao.

:: Hypertension, 巻 39, 番号 1, 05.02.2002, p. 29-34.

研究成果: ジャーナルへの寄稿記事

Kansui, Yasuo ; Fujii, Koji ; Goto, Kenichi ; Abe, Isao. / Bradykinin enhances sympathetic neurotransmission in rat blood vessels. :: Hypertension. 2002 ; 巻 39, 番号 1. pp. 29-34.
@article{1f2cceb7a4a94ea9b0ab1bfeef41cc34,
title = "Bradykinin enhances sympathetic neurotransmission in rat blood vessels",
abstract = "Bradykinin evokes endothelium-dependent relaxation in some vascular beds; on the other hand, the possibility has been demonstrated that in certain organs, such as the adrenal medulla or atria, bradykinin may enhance transmitter release from the sympathetic nerves. We hypothesized that bradykinin may also enhance postganglionic sympathetic neurotransmission in blood vessels. To test this hypothesis, we recorded excitatory junction potentials (EJPs), a measure of sympathetic purinergic neurotransmission, in rat mesenteric resistance arteries with a conventional microelectrode technique. EJPs were elicited by repetitive perivascular nerve stimulation (1 Hz, 20 to 50 V, 30 to 60 μs, 11 pulses). In this preparation, bradykinin (10-7 or 10-6 mol/L) significantly enhanced the amplitude of EJPs without altering the resting membrane potential. This effect of bradykinin was blocked by Hoe 140, a bradykinin B2 receptor antagonist, but not by des-Arg9,[Leu8]-bradykinin, a bradykinin B1 receptor antagonist. The cyclooxygenase inhibitor indomethacin or NO synthase inhibitor NG-nitro-L-arginine did not alter the effect of bradykinin. Captopril, an ACE inhibitor, but not candesartan, an angiotensin II type 1 receptor antagonist, enhanced the action of a low concentration (10-8 mol/L) of bradykinin on EJPs. These findings suggest that in rat mesenteric resistance arteries, bradykinin enhances sympathetic purinergic neurotransmission, presumably through presynaptic bradykinin B2 receptors. The clinical relevance of the present findings remains unclear; however, the fact that the ACE inhibitor, but not the angiotensin II type 1 receptor antagonist, enhanced the action of bradykinin on sympathetic neurotransmission may warrant further investigation.",
author = "Yasuo Kansui and Koji Fujii and Kenichi Goto and Isao Abe",
year = "2002",
month = "2",
day = "5",
doi = "10.1161/hy0102.098309",
language = "English",
volume = "39",
pages = "29--34",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Bradykinin enhances sympathetic neurotransmission in rat blood vessels

AU - Kansui, Yasuo

AU - Fujii, Koji

AU - Goto, Kenichi

AU - Abe, Isao

PY - 2002/2/5

Y1 - 2002/2/5

N2 - Bradykinin evokes endothelium-dependent relaxation in some vascular beds; on the other hand, the possibility has been demonstrated that in certain organs, such as the adrenal medulla or atria, bradykinin may enhance transmitter release from the sympathetic nerves. We hypothesized that bradykinin may also enhance postganglionic sympathetic neurotransmission in blood vessels. To test this hypothesis, we recorded excitatory junction potentials (EJPs), a measure of sympathetic purinergic neurotransmission, in rat mesenteric resistance arteries with a conventional microelectrode technique. EJPs were elicited by repetitive perivascular nerve stimulation (1 Hz, 20 to 50 V, 30 to 60 μs, 11 pulses). In this preparation, bradykinin (10-7 or 10-6 mol/L) significantly enhanced the amplitude of EJPs without altering the resting membrane potential. This effect of bradykinin was blocked by Hoe 140, a bradykinin B2 receptor antagonist, but not by des-Arg9,[Leu8]-bradykinin, a bradykinin B1 receptor antagonist. The cyclooxygenase inhibitor indomethacin or NO synthase inhibitor NG-nitro-L-arginine did not alter the effect of bradykinin. Captopril, an ACE inhibitor, but not candesartan, an angiotensin II type 1 receptor antagonist, enhanced the action of a low concentration (10-8 mol/L) of bradykinin on EJPs. These findings suggest that in rat mesenteric resistance arteries, bradykinin enhances sympathetic purinergic neurotransmission, presumably through presynaptic bradykinin B2 receptors. The clinical relevance of the present findings remains unclear; however, the fact that the ACE inhibitor, but not the angiotensin II type 1 receptor antagonist, enhanced the action of bradykinin on sympathetic neurotransmission may warrant further investigation.

AB - Bradykinin evokes endothelium-dependent relaxation in some vascular beds; on the other hand, the possibility has been demonstrated that in certain organs, such as the adrenal medulla or atria, bradykinin may enhance transmitter release from the sympathetic nerves. We hypothesized that bradykinin may also enhance postganglionic sympathetic neurotransmission in blood vessels. To test this hypothesis, we recorded excitatory junction potentials (EJPs), a measure of sympathetic purinergic neurotransmission, in rat mesenteric resistance arteries with a conventional microelectrode technique. EJPs were elicited by repetitive perivascular nerve stimulation (1 Hz, 20 to 50 V, 30 to 60 μs, 11 pulses). In this preparation, bradykinin (10-7 or 10-6 mol/L) significantly enhanced the amplitude of EJPs without altering the resting membrane potential. This effect of bradykinin was blocked by Hoe 140, a bradykinin B2 receptor antagonist, but not by des-Arg9,[Leu8]-bradykinin, a bradykinin B1 receptor antagonist. The cyclooxygenase inhibitor indomethacin or NO synthase inhibitor NG-nitro-L-arginine did not alter the effect of bradykinin. Captopril, an ACE inhibitor, but not candesartan, an angiotensin II type 1 receptor antagonist, enhanced the action of a low concentration (10-8 mol/L) of bradykinin on EJPs. These findings suggest that in rat mesenteric resistance arteries, bradykinin enhances sympathetic purinergic neurotransmission, presumably through presynaptic bradykinin B2 receptors. The clinical relevance of the present findings remains unclear; however, the fact that the ACE inhibitor, but not the angiotensin II type 1 receptor antagonist, enhanced the action of bradykinin on sympathetic neurotransmission may warrant further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0036155581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036155581&partnerID=8YFLogxK

U2 - 10.1161/hy0102.098309

DO - 10.1161/hy0102.098309

M3 - Article

C2 - 11799074

AN - SCOPUS:0036155581

VL - 39

SP - 29

EP - 34

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1

ER -